The NLRP3 inflammasome as a target for sensorineural hearing loss

被引：9
|
作者：
Gregory, Grace E. [1 ,2 ,3 ]
Munro, Kevin J. [4 ,5 ]
Couper, Kevin N. [2 ,3 ]
Pathmanaban, Omar N. [1 ,2 ,3 ,6 ]
Brough, David [1 ,2 ,3 ]
机构：
[1] Univ Manchester, Fac Biol Med & Hlth, Sch Biol Sci, Div Neurosci,Manchester Acad Hlth Sci Ctr, Manchester, England
[2] Univ Manchester, Geoffrey Jefferson Brain Res Ctr, Manchester Acad Hlth Sci Ctr, Northern Care Alliance NHS Grp, Manchester, England
[3] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Manchester, England
[4] Univ Manchester, Manchester Ctr Audiol & Deafness, Sch Hlth Sci, Manchester, England
[5] Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, England
[6] Salford Royal Hosp NHS Fdn Trust, Manchester Ctr Clin Neurosci, Dept Neurosurg, Salford, England
来源：
CLINICAL IMMUNOLOGY | 2023年 / 249卷
基金：
英国医学研究理事会;
关键词：
Sensorineural hearing loss; Inflammation; Cochlea; NLRP3; inflammasome; Interleukin-1;
D O I：
10.1016/j.clim.2023.109287
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Sensorineural hearing loss is the most common type of hearing loss in adults and occurs due to damage of the inner ear caused by a range of factors including ageing, excessive noise, toxins, and cancer. Auto-inflammatory disease is also a cause of hearing loss and there is evidence that inflammation could contribute to hearing loss in other conditions. Within the inner ear there are resident macrophage cells that respond to insults and whose activation correlates with damage. The NLRP3 inflammasome is a multi-molecular pro-inflammatory protein complex that forms in activated macrophages and may contribute to hearing loss. The aim of this article is to discuss the evidence for the NLRP3 inflammasome and associated cytokines as potential therapeutic targets for sensorineural hearing loss in conditions ranging from auto-inflammatory disease to tumour-induced hearing loss in vestibular schwannoma.
引用
收藏
页数：5
相关论文
共 50 条
  • [1] The NLRP3 Inflammasome as a Pharmacological Target
    Marchetti, Carlo
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2019, 74 (04) : 285 - 296
  • [2] Mitochondrial dysfunction in hearing loss: Oxidative stress, autophagy and NLRP3 inflammasome
    Li, Peipei
    Li, Shen
    Wang, Le
    Li, Hongmin
    Wang, Yang
    Liu, Hongbing
    Wang, Xin
    Zhu, Xiaodan
    Liu, Zhangsuo
    Ye, Fanglei
    Zhang, Yuan
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [3] NLRP3 Ubiquitination-A New Approach to Target NLRP3 Inflammasome Activation
    Akther, Mahbuba
    Haque, Md Ezazul
    Park, Jooho
    Kang, Tae-Bong
    Lee, Kwang-Ho
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [4] NLRP3 inflammasome: a promising target in ischemic stroke
    Gao, Li
    Dong, Qing
    Song, Zhenghong
    Shen, Fei
    Shi, Jianquan
    Li, Yansheng
    INFLAMMATION RESEARCH, 2017, 66 (01) : 17 - 24
  • [5] NLRP3 inflammasome: a promising target in ischemic stroke
    Li Gao
    Qing Dong
    Zhenghong Song
    Fei Shen
    Jianquan Shi
    Yansheng Li
    Inflammation Research, 2017, 66 : 17 - 24
  • [6] NLRP3 inflammasome in hepatic diseases: A pharmacological target
    Ramos-Tovar, Erika
    Muriel, Pablo
    BIOCHEMICAL PHARMACOLOGY, 2023, 217
  • [7] Drugs to Inhibit the NLRP3 Inflammasome: Not Always On Target
    Mauro, Adolfo Gabriele
    Bonaventura, Aldo
    Abbate, Antonio
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2019, 74 (03) : 225 - 227
  • [8] NLRP3 INFLAMMASOME
    Shen, Jianxiao
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 404 - 404
  • [9] Novel mutation in NLRP3 Exon 7 results in sensorineural hearing loss without chronic inflammation
    L Broderick
    S Cherukumilli Grevich
    C Putnam
    H Hoffman
    Pediatric Rheumatology, 13 (Suppl 1)
  • [10] The Potential of NLRP3 Inflammasome as a Therapeutic Target in Neurological Diseases
    He, Wenfang
    Hu, Zhiping
    Zhong, Yanjun
    Wu, Chenfang
    Li, Jinxiu
    MOLECULAR NEUROBIOLOGY, 2023, 60 (05) : 2520 - 2538
12345